Most pharmaceutical businesses are slow-moving by nature due to the lengthy amount of time it takes to develop a new medicine ...

At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $164.99 which represents a decrease of $-4.64 or -2.74% from the prior close of $169.63. The stock opened at $169.63 and touched a ...

Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you ...

AbbVie has rewarded shareholders again with a quarterly dividend. As a Dividend King, it is the epitome of a steady and ...

we should understand the company’s fundamentals and its strengths and weaknesses to better analyze how to play the stock after the recent price dip. ABBV’s Successful New Drugs — Skyrizi and ...

The firm currently has an “outperform” rating on the stock. BMO Capital Markets’ target price suggests a potential upside of 22.02% from the company’s previous close. ABBV has been the ...

AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for ...

AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia ...